Teva Acquires BXCL501, Targeting At-Home Agitation Care

Teva Pharmaceutical has acquired worldwide rights to BXCL501 from BioXcel Therapeutics, adding a late-stage investigational asset to its neuroscience pipeline. The transaction, completed through a court-supervised sale under Section 363 of the U.S. Bankruptcy Code, includes an upfront payment of $57.5 million and up to $67.5 million in contingent regulatory and commercial milestone payments.

BXCL501 is a proprietary, orally dissolving sublingual film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. Its supplemental New Drug Application (sNDA) is under review by the U.S. Food and Drug Administration (FDA) for at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults.

If approved, BXCL501 could become the first FDA-approved treatment specifically intended for patients to manage these episodes at home. The acquisition also includes IGALMI (dexmedetomidine) sublingual film, which is already FDA-approved for the same indication in adults in a medically supervised setting.

At-Home Treatment Could Extend Existing Use

Acute agitation can escalate rapidly and create challenges for patients, families and caregivers. Episodes may require urgent medical assessment or hospital-based intervention, while treatment options for managing agitation outside healthcare settings remain limited.

Teva’s acquisition positions the company to pursue a potential extension of dexmedetomidine sublingual film from supervised clinical settings to at-home use. The proposed approach could allow eligible patients to receive treatment closer to the onset of an episode, although its practical benefits will depend on FDA approval, appropriate patient selection and safe use outside hospitals.

“Agitation can escalate quickly, which is why the ability to intervene early matters,” said Eric Hughes, M.D., Ph.D., executive vice president, global R&D and chief medical officer at Teva. He said that, if approved, BXCL501 could enable adults with schizophrenia or bipolar I or II disorder to treat agitation at home before symptoms become more difficult to manage.

Phase 3 Findings Support Further Evaluation

The sNDA is supported by the SERENITY At-Home Phase 3 trial, which evaluated the safety and tolerability of a 120-microgram dose of BXCL501 in the home setting over 12 weeks. The trial was not powered to establish efficacy, making its reported symptom-related findings exploratory.

Exploratory analyses showed a statistically significant reduction in the modified Clinical Global Impression-Severity (mCGI-S) score from baseline compared with placebo at two hours across treated episodes.

Complete resolution of agitation was reported in 50% of episodes treated with BXCL501, compared with 33% of placebo-treated episodes (p<0.0001). Among episodes classified as severe, complete resolution occurred in 61% of BXCL501-treated episodes versus 18% with placebo (p<0.0001).

The findings suggest a potential treatment effect across different levels of agitation severity. However, the episode-level results should not be interpreted as definitive evidence of efficacy. They are exploratory outcomes from a study primarily designed to assess safety and tolerability, and they do not establish whether at-home treatment reduces emergency department visits or hospitalizations.

The trial also reported reductions in mCGI-S scores with repeat dosing. Mean reductions of 1.2 points were observed following the first 12 doses and 1.4 points following 13 or more doses, with benefits reported throughout the 12-week study. These observations provide additional information on repeated use but do not replace the need for confirmatory efficacy evidence.

FDA Review and Commercial Significance

The FDA is reviewing the BXCL501 sNDA for the proposed at-home indication. Approval would expand the potential use of dexmedetomidine sublingual film beyond its existing hospital-based indication, although the investigational product’s regulatory outcome remains uncertain.

For Teva, the acquisition aligns with its Pivot to Growth strategy, which emphasizes targeted external innovation and late-stage opportunities in areas including neuroscience and immunology. The company intends to use its commercial infrastructure to support a potential launch if the FDA approves BXCL501.

Evan Lippman, executive vice president of business development at Teva, described the asset as a strategic fit with the company’s neuroscience portfolio and its focus on differentiated, late-stage opportunities.

The transaction follows BioXcel Therapeutics’ efforts to sell assets through a court-supervised process. Teva’s acquisition provides a new commercial development pathway for BXCL501, while transferring responsibility for advancing the asset to a company with an established pharmaceutical commercial infrastructure.

What the Acquisition Means

The deal gives Teva an opportunity to expand an existing treatment approach into a setting where options remain limited. The clinical findings provide an encouraging basis for further evaluation, particularly for episodes classified as severe, but the trial’s exploratory efficacy analyses should be interpreted cautiously.

The next decisive step is the FDA’s regulatory decision. If approved, BXCL501 could introduce a new at-home treatment option for acute agitation associated with schizophrenia or bipolar disorder. Until then, its clinical and commercial impact will depend on the strength of the regulatory evidence and the conditions governing its eventual use.

References

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline, Teva Pharmaceutical Industries, October 27, 2026.

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia, BioXcel Therapeutics, 10 September 2026